Quantcast
Last updated on April 17, 2014 at 10:25 EDT

Latest Pemetrexed Stories

2012-09-28 02:24:39

RIDGEFIELD, Conn., Sept. 28, 2012 /PRNewswire/ -- Boehringer Ingelheim today announced new patient-reported health-related outcomes for its investigational oncology compound afatinib,* including lung cancer-related symptoms and quality of life (QoL). These data are secondary endpoints of LUX-Lung 3, a Phase III trial of afatinib (n=230) compared to chemotherapy (pemetrexed/cisplatin) (n=115) in patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell...

2012-09-06 02:32:41

INDIANAPOLIS, Sept. 6, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the Phase III POINTBREAK trial did not meet its primary endpoint of improved overall survival for patients with nonsquamous non-small cell lung cancer (NSCLC) who were randomized to receive a combination of ALIMTA(®) (pemetrexed for injection) with bevacizumab (AVASTIN(®)) and carboplatin induction followed by ALIMTA plus bevacizumab maintenance-the ALIMTA arm-compared to the combination...

2012-08-24 06:23:22

INDIANAPOLIS, Aug. 24, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a prior ruling by the U.S. District Court for the District of Delaware that the company's compound patent for Alimta(®) (pemetrexed) is valid. The compound patent provides protection for Alimta in the U.S. through January of 2017. "We are pleased with today's ruling from the Court of Appeals affirming the validity of the...

2012-07-26 23:29:17

Patients with the most common type of lung cancer are notoriously insensitive to chemotherapy drugs, including cisplatin. New findings related to the cellular pathways that regulate responses to cisplatin have now been published by Cell Press on July 26th in the journal Cell Reports. The findings reveal a potential biomarker that can be used to predict how these patients will respond to chemotherapy, as well as the patients' overall prognosis, paving the way for personalized treatment...

2012-06-05 02:27:45

--Company to Host Conference Call to Discuss Randomized Phase II Program-- CALGARY, June 5, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) announced today that it has entered into an agreement whereby the NCIC Clinical Trials Group (CTG) at Queen's University in Kingston, Ontario, will sponsor and conduct a randomized Phase II study of REOLYSIN(®) in patients with advanced or metastatic non-small cell lung cancer ("NSCLC"). "This agreement...

2012-06-04 02:26:45

INDIANAPOLIS, June 4, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results of a Phase II trial evaluating ALIMTA® (pemetrexed for injection) in combination with a platinum chemotherapy and radiation for patients with locally advanced non-small cell lung cancer (NSCLC). The findings will be presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. on June 4, 2012. "The current standard of care for many patients facing...

2012-06-04 02:26:41

INDIANAPOLIS, June 4, 2012 /PRNewswire/ -- Final results from PARAMOUNT, a Phase III study of ALIMTA(® )(pemetrexed for injection) in the continuation maintenance setting, demonstrated improved overall survival in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) treated with ALIMTA continuation maintenance, according to data announced today by Eli Lilly and Company (NYSE: LLY). PARAMOUNT results will be presented on Monday, June 4, at the 48th Annual...

2012-06-04 02:25:40

LUX-Lung 3 trial results highlighted at the official ASCO Press Conference: Afatinib* delays lung cancer progression compared to standard chemotherapy BURLINGTON, ON, June 4, 2012 /CNW/ - The LUX-Lung 3 Phase III results showed that lung cancer patients taking the novel compound afatinib*, an irreversible ErbB Family Blocker, as a first-line treatment, lived for almost one year before their disease progressed (progression-free survival (PFS) of 11.1 months) versus just over half a...

2012-06-03 18:20:30

RIDGEFIELD, Conn., June 4, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the company's pivotal Phase III clinical trial, LUX-Lung 3, investigating afatinib as a first-line treatment in patients with stage IIIb or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation, met its primary endpoint of progression-free survival (PFS). The study evaluated 345 patients with NSCLC across a variety of EGFR mutations....

2012-05-30 10:24:59

MEMPHIS, Tenn., May 30, 2012 /PRNewswire-USNewswire/ -- The West Clinic, the Mid-South's premier cancer center and world-class center of excellence in medical oncology, hematology, oncologic imaging, breast surgery, clinical research and other advanced medical care, announced today six of its physician-researchers will participate in over a dozen presentations at the 48th Annual American Society of Clinical Oncology (ASCO) Meeting, the premier international scientific oncology...